When patients with MASLD have major metabolic improvement on modern anti-obesity/antidiabetic therapies, how do you interpret changes in NITs over time—do you re-stage prognosis based on updated values, and what magnitude/duration of change is sufficient to de-escalate or escalate liver- specific surveillance?

For MASLD patients receiving HCC surveillance for NIT-defined F3 fibrosis, what would let you stop surveillance after major metabolic improvement on anti-obesity/antidiabetic therapy?

• NITs suggesting F2 or lower on one assessment
• NITs suggesting F2 or lower on two consecutive annual assessments
• NITs suggesting F2 or lower on three consecutive annual assessments
• I would not stop based on NIT improvement alone
• Other